BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24325471)

  • 1. Significance of MDM2-309 polymorphisms and induced corresponding plasma MDM2 levels in susceptibility to laryngeal squamous cell carcinoma.
    Zhou J; Liu F; Zhang D; Chen B; Li Q; Zhou L; Lu LM; Tao L
    DNA Cell Biol; 2014 Feb; 33(2):88-94. PubMed ID: 24325471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
    Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
    Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the recurrence of vocal leukoplakia with MDM2-309 variants over a 2-year period: a prospective study.
    Zhou J; Yang Y; Zhang D; Zhou L; Liu F; Tao L; Lu LM
    Acta Otolaryngol; 2016; 136(1):95-9. PubMed ID: 26371559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms and plasma levels of BCL11A contribute to the development of laryngeal squamous cell carcinoma.
    Zhou J; Yang Y; Zhang D; Zhou L; Tao L; Lu LM
    PLoS One; 2017; 12(2):e0171116. PubMed ID: 28225775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Cytokeratin-1 Single-Nucleotide Polymorphism and Protein Level in Susceptibility to Vocal Leukoplakia and Laryngeal Squamous Cell Carcinoma.
    Yang Y; Zhou J; Wu H
    ORL J Otorhinolaryngol Relat Spec; 2019; 81(2-3):121-129. PubMed ID: 31067553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the microsatellite (GT)n repeat polymorphisms of the HO-1 gene promoter and corresponding serum levels with the risk of laryngeal squamous cell carcinoma.
    Tang D; Tang WJ; Shi XL; Li WP; Zhou H; Lu LM; Tao L
    Acta Otolaryngol; 2016 Aug; 136(8):806-11. PubMed ID: 27400252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
    Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
    Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
    Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population.
    Zhou G; Zhai Y; Cui Y; Zhang X; Dong X; Yang H; He Y; Yao K; Zhang H; Zhi L; Yuan X; Qiu W; Zhang X; Shen Y; Qiang B; He F
    Clin Cancer Res; 2007 May; 13(9):2627-33. PubMed ID: 17473193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
    Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
    Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.
    Dong J; Ren B; Hu Z; Chen J; Hu L; Dai J; Jin G; Xu L; Shen H
    Mol Carcinog; 2011 Jun; 50(6):433-8. PubMed ID: 21268124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
    Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
    Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53/MDM2 Co-Expression in Laryngeal Squamous Cell Carcinoma Based on Digital Image Analysis.
    Chrysovergis A; Papanikolaou V; Tsiambas E; Stavraka C; Ragos V; Peschos D; Psyrri A; Mastronikolis N; Kyrodimos E
    Anticancer Res; 2019 Aug; 39(8):4137-4142. PubMed ID: 31366498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between MDM2 rs769412 and rs937283 polymorphisms with alcohol drinking and laryngeal carcinoma risk.
    Wang H; Ma K
    Int J Clin Exp Pathol; 2015; 8(6):7436-40. PubMed ID: 26261649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
    Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS
    Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
    Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
    Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.